Citations

Clear

3942 citation(s) found for "To, Van".

PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).
Petrylak, Daniel P. , Heijden, Michiel Simon Van Der, O’Donnell, Peter H. , Retz, Margitta, Grivas, Petros , Boyd, Zachary, Nickles, Dorothee , Hegde, Priti S., Mariathasan, Sanjeev , Rosenberg, Jonathan E , Necchi, Andrea , Loriot, Yohann , Perez‐Gracia, José Luis , Bellmunt, Joaquim , Joseph, Richard W. , Fong, Lawrence , Kadel, Edward E. , Frampton, Garrett M. , Bourgon, Richard , Powles, Thomas

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 104-104

10.1200/jco.2016.34.15_suppl.104 Get It

Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.
Nanda, Rita , Liu, Minetta C. , Asare, Smita , Hylton, Nola, Veer, Laura van’t, Perlmutter, Jane , Chien, A. Jo , Forero‐Torres, Andres , Ellis, Erin D. , Han, Heather, Clark, Amy S. , Albain, Kathy S. , Berry, Donald A. , Esserman, Laura, Yau, Christina , Wallace, Anne M. , Boughey, Judy C. , Elias, Anthony , Yee, Douglas , DeMichele, Angela

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 506-506

10.1200/jco.2017.35.15_suppl.506 Get It

506 Background: Pembro is an anti-PD-1 antibody with single agent activity in HER2– metastatic BC. I-SPY 2 is a multicenter, phase 2 platform trial which evaluates novel neoadjuvant therapies; the primary endpoint is pathological complete response (pCR, ypT0/Tis ypN0). We report current efficacy results, with final results at ASCO. Methods: Patients (pts) with invasive BC ≥2.5 cm by exam or ≥2 cm by imaging are assigned weekly paclitaxel x 12 (control) +/- an experimental agent, followed by doxorubicin/cyclophosphamide x 4. Combinations of hormone-receptor (HR), HER2, & MammaPrint (MP) status define the 8 signatures studied. MP low HR+ BC is excluded. Adaptive randomization is based on each arm’s Bayesian probability of superiority over control. Graduation by signature is based on an arm’s Bayesian predictive probability of a successful 1:1 randomized phase 3 trial with a pCR endpoint. We provide raw & Bayesian estimated pCR rates adjusted for covariates, time effects over the course of the trial, & serial MRI modeling for pts not yet assessed for pCR surgically. Results: 69 pts were randomized to pembro (HER2- subsets only) from Dec 2015 until it graduated in Nov 2016. 46 pts have undergone surgery (table); the other 23 have on-therapy MRI assessments. In 29 HR–/HER2– (TNBC) pts, pembro increased raw & estimated pCR rates by >50% & 40%, respectively; in 40 HR+/HER– pts, it did so by 13% and 21%. 5 pts had immune-related grade 3 adverse events (AEs); 1 hypophysitis & 4 adrenal insufficiency. 4 pts presented after completion of AC (149-179 d after starting pembro); 1 presented prior to AC (37 d after starting pembro). 7 pts had grade 1-2 thyroid abnormalities. Conclusion: Pembro added to standard therapy improved pCR rates in all HER2- BCs that meet I-SPY 2 eligibility, especially in TNBC. Immune-mediated AEs were observed; pt follow up is ongoing. Clinical trial information: NCT01042379. [Table: see text]
A Capacity Allocation Planning Model for Integrated Care and Access Management
Deglise‐Hawkinson, Jivan, Huschka, Todd R., Kaufman, David L. , Oyen, Mark P. Van , Huschka, Todd, Helm, Jonathan Eugene

Mayo Clinic

Production and Operations Management | September 6, 2018 | Volume: 27 | Issue: 12 | Pages: 2270-2290

10.1111/poms.12941 | PMID 30930608 Get It

The prevailing first‐come‐first‐served approach to outpatient appointment scheduling ignores differing urgency levels, leading to unnecessarily long waits for urgent patients. In data from a partner healthcare organization, we found in some departments that urgent patients were inadvertently waiting longer for an appointment than non‐urgent patients. This study develops a capacity allocation optimization methodology that reserves appointment slots based on urgency in a complicated, integrated care environment where multiple specialties serve multiple types of patients. This optimization reallocates network capacity to limit access delays (indirect waiting times) for initial and downstream appointments differentiated by urgency. We formulate this problem as a queueing network optimization and approximate it via deterministic linear optimization to simultaneously smooth workloads and guarantee access delay targets. In a case study of our industry partner we demonstrate the ability to (i) reduce urgent patient mean access delay by 27% with only a 7% increase in mean access delay for non‐urgent patients, and (ii) increase throughput by 31% with the same service levels and overtime.
Micro-RNAS Regulate Metabolic Syndrome-induced Senescence in Porcine Adipose Tissue-derived Mesenchymal Stem Cells through the P16/MAPK Pathway
Eirin, Alfonso , Zhu, Xingen , Hickson, LaTonya J. , Wijnen, André J. van , Lerman, Lilach O. , van Wijnen, Andre J , Hickson, LaTonya J , Eirin, Alfonso , Meng, Yu , Zhu, X.-Y., Tang, Hui Ru , Lerman, Amir

Mayo Clinic

Cell Transplantation | September 6, 2018 | Volume: 27 | Issue: 10 | Pages: 1495-1503

10.1177/0963689718795692 | PMID 30187775 Get It

Mesenchymal stem cells (MSCs) constitute an important repair system, but may be impaired by exposure to cardiovascular risk factors. Consequently, adipose tissue-derived MSCs from pigs with the metabolic syndrome (MetS) show decreased vitality. A growing number of microRNAs (miRNAs) are recognized as key modulators of senescence, but their role in regulating senescence in MSC in MetS is unclear. We tested the hypothesis that MetS upregulates in MSC expression of miRNAs that can serve as post-transcriptional regulators of senescence-associated (SA) genes. MSCs were collected from swine abdominal adipose tissue after 16 weeks of Lean or Obese diet ( n = 6 each). Next-generation miRNA sequencing (miRNA-seq) was performed to identify miRNAs up-or down-regulated in MetS-MSCs compared with Lean-MSCs. Functional pathways of SA genes targeted by miRNAs were analyzed using gene ontology. MSC senescence was evaluated by p16 and p21 immunoreactivity, H2AX protein expression, and SA-β-Galactosidase activity. In addition, gene expression of p16, p21, MAPK3 (ERK1) and MAPK14, and MSC migration were studied after inhibition of SA-miR-27b. Senescence biomarkers were significantly elevated in MetS-MSCs. We found seven upregulated miRNAs, including miR-27b, and three downregulated miRNAs in MetS-MSCs, which regulate 35 SA genes, particularly MAPK signaling. Inhibition of miR-27b in cultured MSCs downregulated p16 and MARP3 genes, and increased MSC migration. MetS modulates MSC expression of SA-miRNAs that may regulate their senescence, and the p16 pathway seems to play an important role in MetS-induced MSC senescence.
SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.
Riedel, Richard F. , Brigman, Brian E. , Attia, Steven , Meyer, Christian F. , Schuetze, Scott M. , Dickson, Mark A. , Hartner, Lee , Tinoco, Gabriel , Tine, Brian Andrew Van, Wagner, Andrew J. , Kirsch, David G. , Riedel, Richard F , Tinoco, Gabriel , Mowery, Yvonne Marie , Ballman, Karla V. , Burgess, Melissa , Chmielowski, Bartosz , Milhem, Mohammed , Reinke, Denise K.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS11588-TPS11588

10.1200/jco.2018.36.15_suppl.tps11588 Get It

Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Gounder, Mrinal M. , Mahoney, Michelle R., Tine, Brian Andrew Van, Ravi, Vinod , Attia, Steven , Deshpande, Hari A. , Conry, Robert M. , Movva, Sujana , Pishvaian, Michael J. , Crawford, Jeffrey , Sabagh, Tarek, Tap, William D. , Lefkowitz, Robert A. , Agaram, Narasimhan P. , Wright, John Joseph, Gupta, Abha A. , Milhem, Mohammed , Maki, Robert G. , Dueck, Amylou C. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11500-11500

10.1200/jco.2018.36.15_suppl.11500 Get It

A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML.
Abboud, Camille N. , Akard, Luke P., Foran, James M. , Frankfurt, Olga, Hsu, Jack W., Lister, John , Pagel, John M. , Schiller, Gary J. , Solh, Melham, Üstün, Celalettin , Wieduwilt, Matthew J. , Janice, Brown, Wong, Alicia , Kellerman, Lois, Syoc, Rodney Van, Mamelok, Rick, Andreadis, Charalambos Babis , Desai, Pinkal , Gill, Saar , Syoc, Rod Van, Ravandi, Farhad

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7043-7043

10.1200/jco.2018.36.15_suppl.7043 Get It

A fully automatic solution for structuring prostate pathology reports.
Prinsen, Peter , Ommering, Robbert van, Janssen, Marco H.M., Loos, Marc L. M. van der, Tahmasebi, Amir , Coons, Samuel, Vincent, Per Henrik , Lindh, Claes , Akre, Olof , Rastinehad, Ardeshir R. , Mynderse, Lance A. , Rastinehad, Ardeshir R , Ommering, Rob van, Loos, Marc, Thompson, Scott, Chang, Paul J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e18586-e18586

10.1200/jco.2018.36.15_suppl.e18586 Get It

Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials.
Chumsri, Saranya , Serie, Daniel, Kachergus, Jennifer M., Warren, Sarah , Colón‐Otero, Gerardo , Hilbers, Florentine , Dooren, Veerle Van, Holmes, Eileen , Werner, Olena, Huober, Jens , Baselga, José , Perez, Edith A. , Moreno‐Aspitia, Alvaro , Thompson, E. Aubrey , Mashadi-Hossein, Afshin , Partridge, Ann H. , Carey, Lisa A. , Cosimo, Serena Di , Sotiriou, Christos P. , Dueck, Amylou C.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 577-577

10.1200/jco.2018.36.15_suppl.577 Get It